Eli Lilly is still celebrating the FDA approval of its amyloid-directed Alzheimer's therapy Kisunla but has had less fortune with a candidate against tau, another well-established drug target for the ...

Despite Trump’s signature, the legislation calling for the release of the files includes major loopholes. The department has said little about its plans.